Nicox (NICXF)
(Delayed Data from OTC)
$0.44 USD
0.00 (0.00%)
Updated Dec 28, 2023 12:11 PM ET
4-Sell of 5 4
F Value D Growth NA Momentum NA VGM
Brokerage Reports
0 items in cart
Nicox SA [NICXF]
Reports for Purchase
Showing records 21 - 40 ( 120 total )
Company: Nicox SA
Industry: Medical - Biomedical and Genetics
2022 Preliminary Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Nicox SA
Industry: Medical - Biomedical and Genetics
Q4 highlights confirm continued Vyzulta growth
Provider: Edison Investment Research Limited
Analyst: HEMAMI P
Company: Nicox SA
Industry: Medical - Biomedical and Genetics
Phase 3 Glaucoma Trial Meets Non-Inferiority Endpoint; Reiterate Buy; Lowering PT to ?8
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Nicox SA
Industry: Medical - Biomedical and Genetics
?10m financing boosts cash runway into Q224
Provider: Edison Investment Research Limited
Analyst: HEMAMI P
Company: Nicox SA
Industry: Medical - Biomedical and Genetics
Revising NCX-470 forecasts after Mont Blanc
Provider: Edison Investment Research Limited
Analyst: HEMAMI P
Company: Nicox SA
Industry: Medical - Biomedical and Genetics
NCX-470 non-inferior to latanoprost in Mont Blanc
Provider: Edison Investment Research Limited
Analyst: HEMAMI P
Company: Nicox SA
Industry: Medical - Biomedical and Genetics
Looking ahead to Mont Blanc study readout
Provider: Edison Investment Research Limited
Analyst: HEMAMI P
Company: Nicox SA
Industry: Medical - Biomedical and Genetics
Revising NCX-470 timelines given Denali delay
Provider: Edison Investment Research Limited
Analyst: HEMAMI P
Company: Nicox SA
Industry: Medical - Biomedical and Genetics
Pivotal Glaucoma Data On the Horizon; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Nicox SA
Industry: Medical - Biomedical and Genetics
Moving towards key Mont Blanc data in Q4
Provider: Edison Investment Research Limited
Analyst: HEMAMI P
Company: Nicox SA
Industry: Medical - Biomedical and Genetics
2Q22 Financial Highlights Reported; Reiterate Buy; Adjusting PT to ?13
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Nicox SA
Industry: Medical - Biomedical and Genetics
Publication Highlights Restoration of Ocular Hemodynamics and Retinal Function by NCX 470
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Nicox SA
Industry: Medical - Biomedical and Genetics
Mont Blanc top-line data timelines pushed forward
Provider: Edison Investment Research Limited
Analyst: HEMAMI P
Company: Nicox SA
Industry: Medical - Biomedical and Genetics
Phase 3 Glaucoma Data to Be Reported Earlier in 4Q22; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Nicox SA
Industry: Medical - Biomedical and Genetics
Eye health portfolio targets large markets
Provider: Edison Investment Research Limited
Analyst: HEMAMI P
Company: Nicox SA
Industry: Medical - Biomedical and Genetics
Company: Nicox SA
Industry: Medical - Biomedical and Genetics
New Chief Executive Officer Appointed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Nicox SA
Industry: Medical - Biomedical and Genetics
2021 Financial Results and 1Q22 Highlights Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Nicox SA
Industry: Medical - Biomedical and Genetics
Phase 2 Glaucoma Trial Data Published; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Nicox SA
Industry: Medical - Biomedical and Genetics
Positive Phase 3 ZERVIATE Data Obtained in China; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R